Leff, Jared A.

Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

Morgan, J. R., Schackman, B. R., Leff, J. A., Linas, B. P., & Walley, A. Y. (2018) · Journal of Substance Abuse Treatment

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 332

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Linas, B. P., Barter, D. M., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., et al. (2015) · Annals of Internal Medicine

Hepatitis C virus researchHealth Systems, Economic Evaluations, Quality of Life

Cited by 101

Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.

Schackman, B. R., Leff, J. A., Polsky, D., Moore, B. A., & Fiellin, D. A. (2012) · Journal of General Internal Medicine

Opioid Use Disorder TreatmentSubstance Abuse Treatment and Outcomes

Cited by 100

Monetary conversion factors for economic evaluations of substance use disorders

McCollister, K., Yang, X., Sayed, B., French, M. T., Leff, J. A., & Schackman, B. R. (2017) · Journal of Substance Abuse Treatment

Health Systems, Economic Evaluations, Quality of LifeSubstance Abuse Treatment and Outcomes

Cited by 43

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1

Linas, B. P., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., Freedberg, K. A., et al. (2017) · Open Forum Infectious Diseases

Hepatitis C virus researchHealth Systems, Economic Evaluations, Quality of Life

Cited by 19